Lantheus Biosciences
As of the edition of 20 October 2026, Lantheus Biosciences runs 17 drugs, 4 of them marketed; it is on route A at 0 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
- Molecular Insight Pharmaceuticals, Inc.: acquired in 2013; successor Progenics Pharmaceuticals, Inc.
- Progenics Pharmaceuticals, Inc.: acquired in 2020
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 1 |
| Went quiet | 8 |
| Stopped | 4 |
| Total | 17 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Methylnaltrexone | none listed | 0 |
| Piflufolastat | Ends 2037 (patent) | 2 |
| Florbetaben | Ends 2029 (patent) | 0 |
| Iobenguane | none listed | 2 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 1 target.
| Target | Route |
|---|---|
| FOLH1 Glutamate carboxypeptidase 2 | Route B |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Lantheus Biosciences needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 20 trials led
- Urinary and reproductive: 14 trials led
- Nervous system: 8 trials led